Information  X 
Enter a valid email address

Midatech Pharma PLC (MTPH)

  Print      Mail a friend

Thursday 06 September, 2018

Midatech Pharma PLC

Notice of Interim Results

RNS Number : 9160Z
Midatech Pharma PLC
06 September 2018
 

 

6 September 2018

 

Midatech Pharma PLC

("Midatech" or the "Company")

 

Notice of Interim Results

 

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products for rare diseases in oncology and immunotherapy, announces that it will release its interim results for the six months ending 30 June 2018 on Thursday 27 September 2018.

 

Dr Craig Cook, Chief Executive Officer, and Nick Robbins-Cherry, Chief Financial Officer, will host a presentation and conference call at 14.00 BST at the offices of Panmure Gordon & Co, One New Change, London, EC4M 9AF. Details of the conference call will be published on the day of results. A recording of the call will be available shortly afterwards at www.midatechpharma.com/presentations-reports.

 

 

- Ends -

 

For more information, please contact:

 

Midatech Pharma PLC

Craig Cook, CEO

+44 (0)1235 888300

www.midatechpharma.com

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Corporate finance: Freddy Crossley / Emma Earl

Corporate broking: James Stearns

+44 (0)20 7886 2500

 

Consilium Strategic Communications (Financial PR)

Mary-Jane Elliott / Nicholas Brown / Angela Gray

+44 (0)20 3709 5700

[email protected]

 

Westwicke Partners (US Investor Relations)

Chris Brinzey

+1 339 970 2843

[email protected]

 

Notes for Editors

 

About Midatech Pharma PLC

Midatech is an international specialty pharmaceutical company focused on developing and commercialising products in oncology and immunotherapy for rare diseases via both in-house and partnered programs.  Our development pipeline of improved chemo- and immune-therapeutic drug candidates utilises Midatech's three platform drug delivery technologies, Midacore™, Q-Sphera™ and Nano-Inclusion technologies: 

-    Midacore™ is a leading gold nanoparticle technology that we are exploiting for targeted delivery of: i) existing chemotherapeutic agents to cancer cells, and ii) antigenic peptides to the immune system for immune-oncology applications.

-    Q-Sphera™ platform: our piezo-electric polymer microsphere technology for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months.

-    Nano-Inclusion platform: a nanosaccharide technology, used to dissolve drugs at the nanoscale for direct brain delivery of aqueous formulations to treat brain tumours

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORLLFIDATIEIIT

a d v e r t i s e m e n t